Should You Be Screened for Lung Cancer?

Educational Articles
Written By Cizzle Bio, Inc.
Illustration about lung cancer screening guidelines, risk factors, and the importance of early detection.

Lung cancer is the leading cause of cancer-related deaths in the United States and globally. The good news? When it’s found early, more treatment options are available, and lives can be saved.

The question you may be asking is: Should I be screened?

The answer depends on your personal risk factors. Understanding those risks is the first step toward protecting your health.

Who Should Be Screened?

Healthcare provider reviewing lung cancer screening eligibility criteria with a patient.

The U.S. Preventive Services Task Force (USPSTF) gives clear, evidence-based recommendations for lung cancer screening. They advise annual screening with low-dose CT (LDCT) for people who:

LDCT scans can detect lung cancer at earlier stages, when treatment can be more effective.

You May Still Be at Risk for Lung Cancer—Even If You Don’t Fit the Guidelines

Environmental and occupational exposures can contribute to lung cancer risk, even among people who have never smoked.

While smoking history is the most well-known risk factor, it’s not the only one. Research shows that lung cancer risk can also increase due to environmental exposures, occupational hazards, and underlying health conditions.

You may be at higher risk if you have:

  • Exposure to radon gas (a leading cause of lung cancer in non-smokers)

  • Exposure to asbestos or other carcinogens

  • Long-term exposure to air pollution, especially fine particulate matter

  • A family history of lung cancer

  • A personal history of chronic lung disease (such as COPD or pulmonary fibrosis)

  • Chronic exposure to wildfire smoke

  • Occupational risks, including firefighting

Studies from organizations like the American Lung Association and the National Cancer Institute continue to show that these factors can increase risk—even among people who have never smoked.

That means some individuals may benefit from talking with their doctor about screening, even if they don’t meet traditional criteria.

The Power of Early Detection

Doctor reviewing a lung scan as part of early lung cancer detection and screening.

Lung cancer often develops silently. By the time symptoms appear, the disease may already be advanced. Early detection changes that.

When lung cancer is found at an early stage:

  • More treatment options are available

  • Outcomes are significantly improved

  • Survival rates increase dramatically

That’s why screening—and new innovations in detection—are so important.

CIZ1B—A New Approach to Early Detection

Blood sample being prepared in a clinical laboratory for biomarker testing.

At Cizzle Bio, we are advancing a new generation of tools designed to support earlier and more accessible detection.

Our CIZ1B biomarker blood test is a groundbreaking, minimally invasive approach that detects a tumor-associated protein, called CIZ1B, linked to early-stage lung cancer. Unlike traditional screening methods alone, this simple blood test is designed to:

  • Help identify lung cancer earlier (Stage I)

  • Support clinical decision-making

  • Complement existing screening tools like LDCT

The CIZ1B test is not a replacement for recommended screening. Instead, it’s a complement to standard diagnostic pathways, helping physicians and patients gain additional insight when it matters most.

The test will be available soon to licensed U.S. healthcare providers through our CLIA-certified laboratory partners.

Take the Next Step

Patient taking the next step by scheduling a healthcare appointment to discuss lung cancer screening.

If you think you may be at risk for lung cancer—whether due to smoking history, environmental exposures, or other factors—don’t wait to take action.

  • Talk with your healthcare provider about your risk

  • Ask whether lung cancer screening is right for you.

  • Stay informed about emerging tools like the CIZ1B biomarker blood test.

Because when it comes to lung cancer, early detection can make all the difference—and your health is worth the conversation.

For more information about our innovative CIZ1B biomarker blood test, coming soon to U.S. healthcare providers, please visit: www.cizzlebio.com

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next

The Science Behind CIZ1B for Early Lung Cancer Detection